JPRN-UMIN000032637尚未招募4 期
Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis - Prospective study for effectiveness of Etelcalcetide on dialysis patients
Zenjinkai Shinyokohama Daiichi Clinic Division of Nephrology0 个研究点目标入组 20 人开始时间: 2018年6月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
The study has discontinued.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients decided as incompetent for this study by the doctor Patietns showing contraindication for PARSABIV Patients showing low Ca(<8.4) before admonistration of PARSABIV Patients having malignant diseases Patients having serious diseases in liver, kidney (other than CRF), and heart. Patients treated with cinacalcet or bisphosphonate
研究者
相似试验
已完成
不适用
Intra-retinal arterial fibrinolysisCentral retinal artery occlusionJPRN-jRCTs031180441Kadonosono Kazuaki3
已完成
不适用
COVIPLA-RCOVID-19, Coronavirus diseaseCOVID-19, coronavirus disease, SARS-CoV-2, 2019-nCoVC000657245JPRN-jRCTs031200124Saito Sho11
已完成
2 期
The development of new treatment for depression by neurofeedback.depressionJPRN-jRCTs062190030Okamoto Yasumasa2
招募中
不适用
Prospective analysis for the usefulness of a new EBUS-TBNA biopsy needleenlarged mediastinal lymph nodesJPRN-UMIN000019232Department of Pulmonary Medicine, Fukushima Medical University School of Medicine22
已完成
2 期
Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUPcancer of unknown primaryCUP, nab-Paclitaxel,CBDCAJPRN-jRCTs051180084Yagi Toshinari17